The fact that the presence of abnormal astrocyte reactivity potentiates Aβ-triggered tau pathology may prove to favor the inclusion of astrocyte reactivity biomarkers in the biomarker modeling1 and biological definitions26 of AD. The gene discussed is MAPT; the disease is Alzheimer disease.